FONR Quote, Financials, Valuation and Earnings

OncoCyte has a net margin of 12.56% compared to Fonar's net margin of -11733.04%. Fonar's return on equity of 6.13% beat OncoCyte's return on equity of -211.42%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand OncoCyte has an analysts' consensus of $4.13 which suggests that it could grow by 98.32%. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

Fonar has a beta of 1.222, which suggesting that the stock is 22.214% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.313%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than OncoCyte quarterly revenues of $115K. Fonar's net income of $3.1M is higher than OncoCyte's net income of -$13.5M. Notably, Fonar's price-to-earnings ratio is 10.87x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.96x versus 31.62x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of 12.56% compared to Fonar's net margin of -209.38%. Fonar's return on equity of 6.13% beat ProPhase Labs's return on equity of -59.59%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs has an analysts' consensus of $21.00 which suggests that it could grow by 3427.63%. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

Fonar has a beta of 1.222, which suggesting that the stock is 22.214% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.304, suggesting its less volatile than the S&P 500 by 130.392%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than ProPhase Labs quarterly revenues of $3.1M. Fonar's net income of $3.1M is higher than ProPhase Labs's net income of -$6.6M. Notably, Fonar's price-to-earnings ratio is 10.87x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.96x versus 0.86x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of 12.56% compared to Fonar's net margin of 13.08%. Fonar's return on equity of 6.13% beat Veracyte's return on equity of -0.84%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte has an analysts' consensus of $43.22 which suggests that it could grow by 6.51%. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

Fonar has a beta of 1.222, which suggesting that the stock is 22.214% more volatile than S&P 500. In comparison Veracyte has a beta of 1.706, suggesting its more volatile than the S&P 500 by 70.591%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are smaller than Veracyte quarterly revenues of $115.9M. Fonar's net income of $3.1M is lower than Veracyte's net income of $15.2M. Notably, Fonar's price-to-earnings ratio is 10.87x while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.96x versus 7.24x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of 12.56% compared to Fonar's net margin of -56.4%. Fonar's return on equity of 6.13% beat XWELL's return on equity of -71.82%.

Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 460%. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

Fonar has a beta of 1.222, which suggesting that the stock is 22.214% more volatile than S&P 500. In comparison XWELL has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.765%.

Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

Fonar quarterly revenues are $25M, which are larger than XWELL quarterly revenues of $8.4M. Fonar's net income of $3.1M is higher than XWELL's net income of -$4.8M. Notably, Fonar's price-to-earnings ratio is 10.87x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.96x versus 0.16x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.